Abstract: The invention relates to isolation of human papillomavirus type 41, partial characterization of its genome and its cloning in pUC 19. This opens up an access to early diagnosis of skin tumors associated with HPV 41.

Abstract: Oxidized derivatives of fibrin and fibrin or fibrinogen degradation products or partial sequences, process for their preparation and their use as medicaments, for diagnosis or as an affinity agent are described.

Abstract: A method for degrading nucleic acids in a waste fermentation solution is disclosed. The method comprises exposing the waste solution to RNases and/or DNases released by autolysis of and/or secreted from Paecilomyces lilaninus which are present in or added to the waste solution. The fermentation of the microorganism occurs under sterile conditions. The microorganism can be transformed with nuclease-encoding genes and added to the waste solution before fermentation. The preferred strain of Paecilomyces lilacinus is DSM 5650.

Abstract: In the pipetting device for mixing liquids, a pipetting tube (7) is located in a receiving arrangement (6), and the receiving arrangement (6) is rotatably (10) mounted in a mounting device (5) and connected via a coupling (12, 13) to an eccentric drive (26).

Abstract: The invention relates to a process for the purification by immunoaffinity chromatography of plasminogen activator inhibitor 2 (PAI-2) and to monoclonal antibodies which are suitable for a process of this type.

Abstract: Amine oxide-containing agents for immunochemical assays are described.The amine oxides are contained in constituents of agents for such assays which are used for receiving samples. The amine oxides are also contained in those constituents of the agent in which the immunochemical reaction takes place. The amine oxides bring about an improvement of the assay result, i.e., they increase the sensitivity of the detection and of the determination of an analyte contained in biological material.

Abstract: Compounds of the formula I ##STR1## in which X denotes a hydrogen atom, a group which irreversibly masks the terminal amino group, or a protecting group which is conventional in peptide chemistry, such as, for example, Boc-, Z- or Fmoc-,A and B may be identical or different and denote an alpha- beta- or gamma-amino acid which comprises 2 to 15 carbon atoms and up to 4 nitrogen atoms, 2 sulfur atoms and 6 oxygen atoms and whose side chain may be substituted, and B, if appropriate, denotes a dipeptide formed from these amino acids,C denotes arginine, Lysine, tyrosine, phenylalanine or tryptophane, and their homologs,R.sub.1 and R.sub.2 are identical or different and denote a hydrogen atom or an alkyl radical having up to 4 carbon atoms,R.sub.3 to R.sub.8 are identical or different and denote hydrogen, an alkyl radical, an alkoxy radical or a halogen radical,Y denotes oxygen, andAn.sup.- denotes an anion, and their water-soluble salts, and a process for their preparation are described.

Abstract: The invention relates to compounds from biopolymers and effector substances which are linked with the aid of derivatives of optically active amino acids in which the amino group has been converted into a maleimido group and the carboxyl group into an active ester group.

Abstract: The protein PP4-X, whose amino acid sequence and the DNA sequence coding for this have been determined, has anticoagulative properties and can be prepared by genetic manipulation. PP4-X is used for therapeutic and diagnostic purposes.

Abstract: The invention relates to a method for the determination of antibodies against lipocortins (annexins) in a body fluid of a species, using proteins from the lipocortin family bound to a solid phase and using a labeled bioaffinity binding partner which is directed against single classes or a plurality of classes of immunoglobulins of this species.

Abstract: Specific fragments of the protein PP15 were prepared by enzyme cleavage. Using statistical data, specific oligonucleotides were selected from the oligonucleotides coding for the specific PP15 fragments. These oligonucleotides were then used as probes to successfully screen a cDNA bank of mature human placenta and isolate the complete cDNA of PP15. The cDNA was sequenced and characterized. This cDNA can be used to prepare PP15 protein in prokaryotic or eukaryotic cells.

Abstract: The invention relates to a method for the detection of the functional activity of plasminogen activators and of their inhibitors and stimulators in biological samples, and to reagents for this method.

Abstract: A method and reagent for determining fibrinogen from undiluted plasma samples. The use of undiluted plasma as sample is made possible by the use of a specific peptide inhibitor of fibrin aggregation in a concentration which permits aggregation of fibrin but with reduced speed, so that coagulation time can be measured easily. The range of fibrinogen concentrations which can be measured is increased as compared to that of known methods, and the measurement can be fully automated without prediluting the sample. A biological fluid, e.g., undiluted plasma, is incubated with a reagent containing at least one inhibitor of fibrin aggregation in an amount effective to increase coagulation time to allow measurement of the fibrin concentration, e.g., a coagulation time of about 50 to 150 seconds at a fibrin concentration of 1 gram/liter, and thrombin, or a protease of analogous activity in an amount, which immediately converts all the fibrinogen into soluble fibrin, e.g., in an excess of at least 20 U per ml of plasma.

Abstract: Amidinophenylalanine derivatives, a process for their preparation, their use and pharmaceutical compositions which contain these compounds are described.

Abstract: The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I, ##STR1## which can optionally also be in the form of an acid addition salt of physiologically acceptable inorganic or organic acids, where R.sup.1 is hydrogen or a hydroxyl group, R.sup.2 is hydrogen, a hydroxyl or a methoxy group, R.sup.3 is hydrogen or a hydroxyl group, R.sup.4 is hydrogen or a hydroxyl group, R.sup.5 hydrogen, a hydroxyl or a methoxycarbonyl group, R.sup.6 is CH.sub.2 CH.sub.3, COCH.sub.3, COCH.sub.2 OH, CHOHCH.sub.3 or CHOHCH.sub.2 OH and R.sup.

Abstract: The invention relates to a process for the purification of streptolysin O (SLO) by means of chromatography and to the use of streptolysin.

Abstract: The invention relates to synthetic peptides which contain certain partial sequences from factor VIIa, the synthesis thereof and the use of these peptides for immunizing an animal and for purifying specific antibodies against the said peptides, to antibodies against these peptides and the use of these antibodies and peptides in therapy and diagnosis.

Abstract: A solution containing antigen and adjuvant for eliciting an immune response. The adjuvant comprises zinc hydroxide or iron hydroxide in an amount sufficient to enhance the immune response elicited by the antigen. A process for preparation of such a solution is also provided.

Abstract: A process for the preparation of an iron-free, pasteurized human transferrin is described and entails human transferrin being pasteurized in the presence of a complexing agent in solution, and the complexing agent being removed with the bound iron.This transferrin can be used as pharmaceutical or growth factor.

Abstract: A process for the production of a pasteurized immunoglobulin preparation is described, which comprises heating a solution of an immunoglobulin in the presence of a carboxylic acid or one of its salts and/or of a saccharide until viable pathogens, which may remain undetected in conventional tests, in particular hepatitis viruses or HTLV III ("Aids") viruses, are inactivated i.e. are rendered incapable of reproduction and/or of being intracellularly or otherwise reproduced.A preparation of this type can be used for therapy or prophylaxis or as component of a diagnostic kit.